Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data

References

• RösslerWSalizeHJvan OsJRiecher-RösslerASize of burden of schizophrenia and psychotic disordersEur Neuropsychopharmacol200515439940915925493
   PubMed Web of Science ®Google Scholar
• SadoMInagakiAKorekiAThe cost of schizophrenia in JapanNeuropsychiatr Dis Treat2013978779823785238
   PubMed Web of Science ®Google Scholar
• LinIMuserEMunsellMBensonCMenzinJEconomic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysisJ Med Econ201426111
   Google Scholar
• FitchKIwasakiKVillaKResource utilization and cost in a commercially insured population with schizophreniaAm Health Drug Benefits201471182624991388
   PubMedGoogle Scholar
• WillisMSvenssonMLöthgrenMErikssonBBerntssonAPerssonUThe impact of schizophrenia-related hospital utilization and cost of switching to long-acting risperidone injections in SwedenEur J Health Econ201011658559420084535
   PubMed Web of Science ®Google Scholar
• FreySThe economic burden of schizophrenia in Germany: a population-based retrospective cohort study using genetic matchingEur Psychiatry201429847948924853296
   PubMed Web of Science ®Google Scholar
• MenzinJBoulangerLFriedmanMMackellJLloydJRTreatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid programPsychiatr Serv200354571972312719504
   PubMed Web of Science ®Google Scholar
• Rummel-KlugeCSchusterTPetersSKisslingWPartial compliance with antipsychotic medication is common in patients with schizophreniaAust N Z J Psychiatry200842538238818473256
   PubMed Web of Science ®Google Scholar
• MarderSROverview of partial complianceJ Clin Psychiatry200364suppl 163914680412
   PubMed Web of Science ®Google Scholar
• LangKMeyersJLKornJRMedication adherence and hospitalization among patients with schizophrenia treated with antipsychoticsPsychiatr Serv201061121239124721123409
   PubMed Web of Science ®Google Scholar
• TafesseEHinesPLCarsonWAtypical antipsychotic adherence and hospitalization in patients with schizophreniaSchizophr Res200360346
   Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDLacroJPDolderCRA prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophreniaJ Clin Psychiatry2006671114112316889456
   PubMed Web of Science ®Google Scholar
• EaddyMGroggALocklearJAssessment of compliance with antipsychotic treatment and resource utilization in a Medicaid populationClin Ther20052726327215811492
   PubMed Web of Science ®Google Scholar
• ValensteinMCopelandLBlowFPharmacy data identify poorly adherent patients with schizophrenia at increased risk for admissionMed Care20024063063912187177
   PubMed Web of Science ®Google Scholar
• AhnJMcCombsJJungCClassifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) programValue Health200811485618237360
   PubMed Web of Science ®Google Scholar
• KozmaCWeidenPPartial compliance with antipsychotics increases mental health hospitalizations in schizophrenic patients: analysis of a national managed care databaseAm Health Drug Benefits20092313825126270
   PubMedGoogle Scholar
• GilmerTDolderCLacroJAdherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophreniaAm J Psychiatry200416169269915056516
   PubMed Web of Science ®Google Scholar
• MorkenGWidenJGraweRNonadherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophreniaBMC Psychiatry200883218447935
   PubMed Web of Science ®Google Scholar
• KnappMKingDPugnerKLapuertaPNon-adherence to antipsychotic medication regimens: associations with resource use and costsBr J Psychiatry200418450951615172945
   PubMed Web of Science ®Google Scholar
• HigashiKMedicGLittlewoodKJDiezTGranströmODe HertMMedication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature reviewTher Adv Psychopharmacol20133420021824167693
   PubMedGoogle Scholar
• GriffithsKMNakaneYChristensenHYoshiokaKJormAFNakaneHStigma in response to mental disorders: a comparison of Australia and JapanBMC Psychiatry200662116716231
   PubMed Web of Science ®Google Scholar
• KimYBerriosGEImpact of the term schizophrenia on the culture of ideograph: the Japanese experienceSchizophr Bull200127218118511354585
   PubMed Web of Science ®Google Scholar
• SatoMRenaming schizophrenia: a Japanese perspectiveWorld Psychiatry200651535516757998
   PubMed Web of Science ®Google Scholar
• OnoYSatsumiYKimYSchizophrenia: is it time to replace the term?Psychiatry Clin Neurosci19995333534110459734
   PubMed Web of Science ®Google Scholar
• JormAFNakaneYChristensenHYoshiokaKGriffithsKMWataYPublic beliefs about treatment and outcome of mental disorders: a comparison of Australia and JapanBMC Med200531216004615
   PubMed Web of Science ®Google Scholar
• HanzawaSNosakiAYatabeKStudy of understanding the internalized stigma of schizophrenia in psychiatric nurses in JapanPsychiatry Clin Neurosci20126611312022353324
   PubMed Web of Science ®Google Scholar
• HanzawaSBaeJKTanakaHFamily stigma and care burden of schizophrenia patients: comparison between Japan and KoreaAsia-Pacific Psychiatry20091120129
   Web of Science ®Google Scholar
• YangMBarnerJWorchelJFactors related to antipsychotic oversupply among central Texas veteransClin Ther20072961214122517692735
   PubMed Web of Science ®Google Scholar
• GraySLMahoneyJEBloughDKMedication adherence in elderly patients receiving home health services following hospital dischargeAnn Pharmacother200135553954511346058
   PubMed Web of Science ®Google Scholar
• SugibayashiYYoshimuraKYamauchiKInagakiAIkegamiNInfluence of patient characteristics on care time in patients hospitalized with schizophreniaNeuropsychiatr Dis Treat2014101577158425187720
   PubMed Web of Science ®Google Scholar
• OchoaSUsallJCoboJLabadXKulkarniJGender differences in schizophrenia and first-episode psychosis: a comprehensive literature reviewSchizophr Res Treatment2012201291619822966451
   PubMedGoogle Scholar
• ShtaselDGurRGallacherFHeimbergCGurRGender differences in the clinical expression of schizophreniaSchizophr Res1992732252311390401
   PubMed Web of Science ®Google Scholar
• BergenSEO’DushlaineCTLeePHGenetic modifiers and subtypes in schizophrenia: investigations of age at onset, severity, sex and family historySchizophr Res20141541–3485324581549
   PubMed Web of Science ®Google Scholar
• SuhHSKangHYKimJShinEEffect of health insurance type on health care utilization in patients with hypertension: a national health insurance database study in KoreaBMC Health Serv Res20141457025412904
   PubMed Web of Science ®Google Scholar
• SmithDJLanganJMcLeanGGuthrieBMercerSWSchizophrenia is associated with excess multiple physical-health comorbidities but low levels of recorded cardiovascular disease in primary care: cross-sectional studyBMJ Open20133e002808
   PubMed Web of Science ®Google Scholar
• BuckleyPFMillerBJLehrerDSCastleDJPsychiatric comorbidities and schizophreniaSchizophr Bull200935238340219011234
   PubMed Web of Science ®Google Scholar
• CoxDRRegression models and life tables (with discussion)J R Stat Soc B197234187220
   Google Scholar
• MaddalaGSIntroduction to Econometrics3rd edNew YorkJohn Wiley and Sons2001
   Google Scholar
• AcostaFJBoschESarmientoGJuanesNCaballero-HidalgoAMayansTEvaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variablesSchizophr Res2009107221321718849150
   PubMed Web of Science ®Google Scholar
• TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry2011168660360921362741
   PubMed Web of Science ®Google Scholar
• Grimaldi-BensoudaLRouillonFAstrucBCGS Study GroupDoes long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS)Schizophr Res20121342–318719422130111
   PubMed Web of Science ®Google Scholar
• LeuchtCHeresSKaneJMKisslingWDavisJMLeuchtSOral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trialsSchizophr Res20111271–3839221257294
   PubMed Web of Science ®Google Scholar
• RossiGFredianiSRossiRRossiALong-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observationsBMC Psychiatry20121212222909285
   PubMed Web of Science ®Google Scholar
• OlivaresJMRodriguez-MoralesADielsJe-STAR Spanish Study GroupLong-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)Eur Psychiatry200924528729619195847
   PubMed Web of Science ®Google Scholar
• OlivaresJMRodriguez-MartinezABurónJAAlonso-EscolanoDRodriguez-MoralesAe-STAR Study GroupCost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in SpainAppl Health Econ Health Policy200861415318774869
   PubMedGoogle Scholar
• GaebelWSchreinerABergmansPRelapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label. Randomized clinical trialNeuropsychopharmacology201035122367237720686456
   PubMed Web of Science ®Google Scholar
• ZeidlerJMahlichJGreinerWHeresSCost-effectiveness of paliperidone palmitate for the treatment of schizophrenia in GermanyAppl Health Econ Health Policy201311550952123975630
   PubMedGoogle Scholar
• RansmayrSMehnertAMahlichJBudget impact analyse von Paliperidon Palmitat im österreichischen Versorgungskontext. [Budget impact analysis of paliperdidone palmitate in the Austrian health care system]Pharmacoecon Ger Res Artic2013112532 German
   Google Scholar
• SpillBKonoppaSKisslingWMainoKMesserTHeresSLong-term observation of patients successfully switched to risperidone long-acting injectable: a retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costsInt J Psychiatry Clin Pract201014536224917233
   PubMed Web of Science ®Google Scholar
• WaddellLTaylorMAttitudes of patients and mental health staff to antipsychotic long-acting injections: systematic reviewBr J Psychiatry2009195s43s50
   Web of Science ®Google Scholar
• WalkupJTMcAlpineDDOlfsonMLabayLEBoyerCHansellSPatients with schizophrenia at risk for excessive antipsychotic dosingJ Clin Psychiatry200061534434810847308
   PubMed Web of Science ®Google Scholar
• IizukaTExperts’ agency problems: evidence from the prescription drug market in JapanRand J Econ200738384486218478669
   PubMed Web of Science ®Google Scholar
• Vila-RodriguezFOchoaSAutonellJUsallJHaroJMComplex interaction between symptoms, social factors, and gender in social functioning in a community-dwelling sample of schizophreniaPsychiatric Q2011824261274
   Web of Science ®Google Scholar
• GrossmanLSHarrowMRosenCFaullRStraussGPSex differences in schizophrenia and other psychotic disorders: a 20-year longitudinal study of psychosis and recoveryCompr Psychiatry200849652352918970899
   PubMed Web of Science ®Google Scholar
• VaskinnASundetKSimonsenCHellvinTMelleIAndreassenOASex differences in neuropsychological performance and social functioning in schizophrenia and bipolar disorderNeuropsychology201125449951021463042
   PubMed Web of Science ®Google Scholar
• BozikasVPKosmidisMHPeltekisASex differences in neuropsychological functioning among schizophrenia patientsAust N Z J Psychiatry201044433334120050721
   PubMed Web of Science ®Google Scholar